5-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-1H-1,2,4-triazole-3-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 5-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-1H-1,2,4-triazole-3-carboxylic acid
• 英文别名: 3-(9H-fluoren-9-ylmethoxycarbonylamino)-1H-1,2,4-triazole-5-carboxylic acid
• 化学式: C₁₈H₁₄N₄O₄
• 分子量: 350.334
• InChiKey: WYWYCVJGMSJQOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  117
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  NΑ-FMOC-NΩ-(2,2,5,7,8-五甲基苯并二氢吡喃-6-磺酰基)-L-精氨酸 、 FMOC-Β-环己基-L-丙氨酸 、 5-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-1H-1,2,4-triazole-3-carboxylic acid 生成 3-amino-N-[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]-1H-1,2,4-triazole-5-carboxamide
  参考文献：
  名称：

  Heterocycle-peptide hybrid compounds. Aminotriazole-containing agonists of the thrombin receptor (PAR-1)

  摘要：

  The thrombin receptor PAR-1 is activated by cl-thrombin to stimulate cells, including platelets, through the tethered-ligand sequence SFLLRN. We have discovered a novel series of heterocycle-peptide hybrids comprised of a tripeptide segment, such as Cha-Arg-Phe, and an N-terminal heterocyclic group, many of which behave as full PAR-1 agonists. Certain compounds with an aminotriazole group, such as 4 and 16, are nearly as potent as SFLLRN-NH2, in inducing platelet aggregation. Also, some arylethenoyl "N-capped" compounds, such as 52 and 57, exhibit mixed PAR-1 agonist-antagonist activity. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00197-3

文献信息

• [EN] SUBSTITUTED HETEROCYCLIC ACYL-TRIPEPTIDES USEFUL AS THROMBIN RECEPTOR MODULATORS<br/>[FR] TRIPEPTIDES ACYLES HETEROCYCLIQUES SUBSTITUES, UTILES COMME MODULATEURS DU RECEPTEUR DE LA THROMBINE
  申请人：ORTHO MCNEIL PHARM INC

  公开号：WO2000035942A1

  公开（公告）日：2000-06-22

  The invention is directed to substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators, their use in wound healing and preventing platelet aggregation. Pharmaceutical compositions comprising the substituted heterocyclic acyl-tripeptides of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.

  本发明涉及用于凝血酶受体调节剂的取代杂环酰基三肽，其在伤口愈合和预防血小板聚集方面有用。本发明还揭示了包括本发明的取代杂环酰基三肽的制药组合物和治疗由凝血酶受体介导的疾病的方法。
• Microrna as ligands and target molecules
  申请人：Griffey H. Richard

  公开号：US20050142581A1

  公开（公告）日：2005-06-30

  The present invention provides methods for the identification of target molecules that bind to ligands, particularly microRNA ligands and mimics thereof and/or microRNA target molecules and mimics thereof, with as little as millimolar (mM) affinity using mass spectrometry. The methods may be used to determine the mode of binding interaction between two or more of these target molecules to the ligand as well as their relative affinities. Also provided are methods for designing compounds having greater affinity to a ligand by identifying two or more target molecules using mass spectrometry methods of the invention and linking the target molecules together to form a novel compound.

  本发明提供了一种使用质谱技术，以毫摩尔（mM）亲和力水平，鉴定与配体结合的靶分子的方法，特别是微RNA配体及其模拟物和/或微RNA靶分子及其模拟物。该方法可用于确定两个或更多这些靶分子与配体之间的结合模式以及它们的相对亲和力。本发明还提供了一种通过使用本发明的质谱技术鉴定两个或更多靶分子，并将这些靶分子连接起来形成新化合物，从而设计具有更高亲和力的配体的方法。
• Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1806356A2

  公开（公告）日：2007-07-11

  The invention is directed to substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators, their use in wound healing and preventing platelet aggregation. Pharmaceutical compositions comprising the substituted heterocyclic acyl-tripeptides of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.

  本发明涉及作为凝血酶受体调节剂的取代杂环酰基三肽、它们在伤口愈合和防止血小板聚集中的用途。还公开了包含本发明的取代杂环酰基三肽的药物组合物和治疗凝血酶受体介导的疾病的方法。
• Design, Synthesis, and In Vitro Activity of Peptidomimetic Inhibitors of Myeloid Differentiation Factor 88
  作者：Nicola Fantò、Grazia Gallo、Andrea Ciacci、Mauro Semproni、Davide Vignola、Marco Quaglia、Valentina Bombardi、Domenico Mastroianni、M. Pia Zibella、Giancarlo Basile、Marica Sassano、Vito Ruggiero、Rita De Santis、Paolo Carminati

  DOI：10.1021/jm070723u

  日期：2008.3.13

  We describe the design and synthesis of a peptidomimetic library derived from the heptapeptide Ac-RDVLPGT-NH(2), belonging to the Toll/IL-1 receptor (TIR) domain of the adaptor protein MyD88 and effective in inhibiting its homodimerization. The ability of the peptidomimetics to inhibit protein-protein interaction was assessed by yeast 2-hybrid assay and further validated in a mammalian cell system by evaluating the inhibition of NF-kappa B activation, a transcription factor downstream of MyD88 signaling pathway that allows production of essential effector molecules for immune and inflammatory responses.
• SUBSTITUTED HETEROCYCLIC ACYL-TRIPEPTIDES USEFUL AS THROMBIN RECEPTOR MODULATORS
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1140985A1

  公开（公告）日：2001-10-10